BURLINGTON, Mass. and
LANSING, Mich., Aug. 12, 2024
/PRNewswire/ -- QSA Global, Inc. (QSA) and Niowave, Inc. (Niowave)
are pleased to announce a partnership to transfer Niowave's
innovative radium-226 (Ra-226) processing technology to QSA and
Co-Develop a Scalable Radium Purification Process. This strategic
partnership marks a significant advancement in the field of
radiopharmaceutical technology, enhancing the supply chain for
critical radioisotopes including actinium-225 (Ac-225).
Since 2017, Niowave has been at the forefront of processing
legacy Ra-226 and actively producing Ac-225. Under the terms of the
partnership, QSA now has a license to leverage Niowave's
state-of-the-art technology to process Ra-226 sources. The
partnership has two components consisting of the development of a
scalable Ra-226 purification process and the delivery of radium to
Niowave to enable increased Ac-225 production. The newly purified
Ra-226 will be supplied to Niowave, increasing Ac-225 production
capacity to exceed 5-10 Ci per year using their Linear Accelerator
Technology.
QSA and Niowave will co-develop a scaled radium purification
process to meet the ever-increasing demand for Ac-225. QSA will
commence multi-year supply of purified Ra-226 to Niowave in early
2025 and extend this supply to third parties in 2026. This
collaboration is expected to significantly increase the
availability of high-purity Ra-226 to the radioisotope ecosystem
and improve the probability that Niowave and other Ac-225
manufacturers can meet the growing demand for Ac-225.
"We are excited to partner with Niowave and leverage their
advanced Ra-226 processing technology," said Jake Bourn, VP/GM at QSA. "This partnership not
only expands and accelerates our capabilities for processing Ra-226
but also helps to meet the increasing demand for Ac-225, which is
crucial for advancing cancer treatments. Together, we are committed
to driving innovation and meeting the growing needs of the
healthcare industry."
Niowave's CEO, Mike Zamiara,
added, "Our partnership with QSA represents a significant step
forward in Niowave's path to maximize Ac-225 capacity. By combining
our expertise with QSA's, we can enhance our production
capabilities, better support our partners, and ensure a stable
supply of Ac-225. We value QSA's deep industry knowledge and look
forward to working with them to drive innovation in the
radioisotope space."
This collaboration signifies a commitment from both companies to
innovate and improve the radiopharmaceutical supply chain,
ultimately benefiting patients and advancing the field of nuclear
medicine.
About QSA Global, Inc.
QSA Global, Inc. is a leading provider of high-quality
radioisotope products and services. With a strong focus on safety,
reliability, and innovation, QSA serves a diverse range of
industries including healthcare, industrial, and environmental
sectors.
About Niowave, Inc.
Niowave, Inc. is a pioneer in the production of medical
isotopes. Utilizing advanced accelerator technology, Niowave
produces critical isotopes for cancer treatment and other medical
applications dedicated to improving patient outcomes and advancing
healthcare.
For media inquiries, please contact:
Mike Zamiara
Chief Executive Officer
Niowave, Inc.
Phone: 517-999-3475
Email: info@niowaveinc.com
Joe Lapinskas, PhD
Director, Innovation & Marketing
QSA Global, Inc.
Phone: 765-532-6892
Email: joe.lapinskas@qsa-global.com
View original
content:https://www.prnewswire.co.uk/news-releases/qsa-global-inc-and-niowave-inc-establish-collaboration-to-improve-radium-purification-increasing-radium-availability-and-ac-225-production-302220087.html